A laboratory technician looking through a microscope
Laboratory technician at work. Photo: Shixart1985, CC BY 2.0, via Wikimedia Commons.

TOKYO, Japan — Japan’s RIKEN research institute and a network of scientific and medical partners have developed a fully automated digital bioanalysis platform designed to make highly sensitive testing faster and less dependent on specialist laboratory staff. The system, known as COWFISH2A+, automates the process from sample loading and measurement through data analysis and reporting. Its developers say the platform uses a microtube-array method for single-molecule detection, an approach intended to identify very small quantities of disease-related molecules in samples such as blood, urine and swabs. In performance evaluations involving clinical nasopharyngeal swab samples, the system recorded approximately 90 per cent sensitivity and specificity for COVID-19 and influenza A and B. The complete process, from loading a sample to receiving a result, took about 15 minutes. The research group includes RIKEN, the Tokyo Metropolitan Institute for Geriatrics and Gerontology, BIOTEC, Institute of Science Tokyo, Kyoto University and Isumi Medical Center. The Science Japan report published on November 20 outlines the technology, while the study appeared in *Cell Reports Physical Science* under the title “COWFISH2A+ as a versatile and accessible platform for digital bioanalysis.”

Two cancer researchers examining test tubes in a laboratory
Researchers examining test tubes in a laboratory. Photo: Rhoda Baer, U.S. National Cancer Institute, public domain.

The development matters because digital bioanalysis and liquid biopsy research often depend on detecting extremely small amounts of biological material. Earlier methods developed by the team, including SATORI for genetic testing and SEAP for single-molecule enzyme profiling, demonstrated the ability to measure biomarkers without conventional amplification in certain applications. However, routine use was limited by workflows that required skilled technicians to prepare samples and analyse results. COWFISH2A+ is intended to address that bottleneck through automated liquid handling, heating and magnetic-control functions, while disposable microchips are being produced using a process adapted from compact-disc manufacturing. The developers say the platform could eventually support research and testing related to cancer, dementia, infectious diseases, drug discovery and agriculture. Those wider uses should not be confused with a validated cancer-screening service: the reported clinical performance evaluation focused on COVID-19 and influenza swab samples, and further protocols and regulatory work are still required. The team plans to begin sales for laboratory-developed testing applications and is pursuing medical-device approval. The planned price is approximately seven million yen. The advance adds to the growing use of computational methods in biomedical research, a subject also explored in HeadlinesXtra’s coverage of AI-assisted drug discovery at major pharmaceutical companies and an AI model analysing heart-device signals to identify periods of elevated arrhythmia risk.